The Quantum BioPharma Ltd. (QNTM) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer in the United States. Quantum BioPharma submits Form 6-K reports under the Securities Exchange Act of 1934, which include press releases, condensed consolidated interim financial statements, management’s discussion and analysis of financial condition and results of operations, material change reports, information circulars, and voting results. These documents give investors insight into the company’s biopharmaceutical activities in neurodegenerative and metabolic disorders and alcohol misuse disorders, as well as its capital markets and corporate actions.
Recent Form 6-K filings incorporate financial statements and MD&A for periods ended September 30, 2025, along with CEO and CFO certificates and related XBRL data. Other 6-Ks attach press releases covering topics such as clinical progress with Lucid-21-302 (Lucid-MS), at-the-market offering agreements, private placements, warrant expirations, and updates on the company’s digital asset portfolio. Additional filings include material change reports and management information circulars that document corporate decisions, shareholder meetings, and changes reported under Canadian securities rules but furnished to the SEC for U.S. investors.
Through these filings, users can review how Quantum BioPharma describes its lead MS program, licensing arrangements for unbuzzd , strategic investments via FSD Strategic Investments Inc., and litigation-linked contingent value rights (CVRs). The filings also reference the company’s registration statement on Form F-3, into which certain 6-K exhibits are incorporated by reference. On Stock Titan, these documents are updated from EDGAR in near real time and are accompanied by AI-powered summaries that highlight key points from each report, helping readers quickly understand financial disclosures, clinical milestones, capital structure changes, and other material information without reading every page.
Investors can use this filings page to locate Quantum BioPharma’s quarterly financial information, narrative analysis, press releases furnished as exhibits, and other regulatory documents that together outline the company’s operations, risk factors referenced in its Canadian and U.S. disclosures, and the evolution of its MS, alcohol health, and investment activities.
Quantum BioPharma Ltd. (QNTM) plans to voluntarily delist its Class B subordinate voting shares from the Canadian Securities Exchange, subject to CSE approval. The Company states this is due to low CSE trading volume relative to the expenses, administrative effort and regulatory burden of maintaining a dual listing.
The delisting will not affect listings on the Nasdaq Capital Market, the Frankfurt Stock Exchange, or Upstream, and the Class B Shares are expected to continue trading on Nasdaq under the symbol QNTM. Subject to CSE approval, the Company expects the last trading day on the CSE to be the close of business on September 4, 2026. Quantum BioPharma will remain a reporting issuer in its Canadian jurisdictions and continue filing continuous disclosure documents on SEDAR+ and with the SEC on EDGAR.
The Company highlights its strategic assets, including a 19.86% ownership interest in Unbuzzd Wellness Inc. as of September 30, 2025, and a royalty on unbuzzd™ sales with tiered rates up to an aggregate $250 million, as well as a portfolio of property-secured loans held through its subsidiary FSD Strategic Investments Inc.
Quantum BioPharma Ltd. reported stronger liquidity and lower costs for the quarter ended June 30, 2026, while advancing its lead program. Combined cash, cash equivalents and digital assets rose to US$9.5 million from US$4.1 million at December 31, 2025, and cash and cash equivalents nearly doubled to US$3.65 million. Management states that, based on the first-half 2026 burn rate, available resources are expected to fund planned operations to at least October 2027.
Total shareholders’ equity increased to US$6.09 million, while working capital improved to about US$1.66 million. Key liquidity ratios strengthened, with a current ratio of 1.2 and quick ratio of 1.19. Operating discipline drove a 53% year-over-year reduction in total operating expenses in the second quarter to US$2.29 million, including a 47% decline in general and administrative expenses, and cash used in operating activities for the first half fell 44% to US$3.46 million.
Subsequent to quarter-end, the FDA approved Quantum’s Investigational New Drug (IND) application for Lucid-MS (Lucid-21-302), clearing the company to begin a randomized, double-blind, placebo-controlled Phase 2 trial in progressive multiple sclerosis. Quantum also continues to benefit from its 19.48% stake and royalty arrangement in Unbuzzd Wellness Inc.
Quantum Biopharma Ltd. (QNTM) reports unaudited results for the three and six months ended June 30, 2026. Total assets were $14,391,885, up from $11,160,909 at December 31, 2025, driven mainly by digital assets of $5,887,655 and cash of $3,647,072.
The company recorded a Q2 net loss of $3,092,936, a sharp improvement from $9,766,327 a year earlier, and a six‑month net loss of $16,846,500 versus $18,506,208 in 2025. Operating expenses for the six months fell to $5,259,895 from $8,250,862, while operating cash outflow narrowed to $3,458,471.
Quantum raised $7,876,531 through an at‑the‑market share program and issued $2,733,109 of March 2026 convertible debentures, creating derivative liabilities of $1,726,994 and a warrant liability of $2,227,505. Significant additional investment of $4,288,191 in digital assets led to an unrealized loss of $2,151,307. Share count increased through ATM issuances, debenture conversions and equity‑settled liabilities.
Quantum BioPharma Ltd. filed an amended Form 6-K/A to update the treatment of a previously furnished August 10, 2026 press release. The amendment’s sole purpose is to furnish that press release again as Exhibit 99.1 and to incorporate it, and the original Form 6-K report, by reference into the company’s Form F-3 registration statement (SEC File No. 333-276264). No new events are reported and the prior disclosures remain unchanged, other than this incorporation-by-reference clarification.
Quantum BioPharma Ltd. reports that the U.S. FDA has approved its Investigational New Drug (IND) application for Lucid-MS (Lucid-21-302), allowing the company to proceed to a randomized, double-blind, placebo-controlled Phase 2 trial in progressive multiple sclerosis. Lucid-MS is a patented, first-in-class neuroprotective candidate designed to inhibit demyelination by targeting protein arginine deiminase 2 (PAD2), aiming to preserve myelin integrity rather than suppress the immune system. The company is working with a leading global clinical research organization, with site selection underway and plans to begin patient enrollment and dosing as quickly as possible. Quantum BioPharma highlights a cash, digital assets and liquid investment position of over USD $10 million as of March 31, 2026 to support development, and notes additional economic exposure through a 19.84% equity stake and tiered royalty rights in Unbuzzd Wellness Inc. in a broader neurology and MS market that third-party research estimates could reach USD $38.62 billion in MS therapeutics by 2030.
Quantum Biopharma Ltd. reports a Schedule 13G filing showing AdvisorShares Trust beneficially owns 203,564 Class B Subordinate Voting Shares, representing 5.33% of that class.
The filing states AdvisorShares Trust holds sole voting and dispositive power over 203,564 shares. The disclosure is signed by the fund's Chief Compliance Officer on 07/08/2026.
Quantum BioPharma reports that the U.S. FDA has placed the Investigational New Drug application for its multiple sclerosis candidate Lucid‑MS (Lucid‑21‑302) on clinical hold pending additional information. The company is reviewing the FDA’s comments and plans to submit a response package with its advisors and development partners.
Quantum is withdrawing previously disclosed timelines for FDA review, initiation of the planned Phase 2 trial, and interim data, which should no longer be relied upon. The company also announces that Dr. Lakshmi P. Kotra resigned as director and from all positions at Quantum and its subsidiaries, effective June 1, 2026, while remaining a senior clinical advisor.
Quantum BioPharma Ltd. has engaged IR Agency LLC, operating as Stocks.news, to provide investor relations, marketing, digital community building, news distribution and lead-generation services. The agreement begins on June 8, 2026, runs for six months and carries a fee of US$250,000.
The Agency is arm’s length to Quantum and neither it nor its principals hold, or have rights to acquire, any Quantum securities. The filing also reiterates Quantum’s business focus on therapies for neurodegenerative and metabolic disorders and alcohol misuse, and highlights its economic interest in Unbuzzd through both an equity stake and royalties.
Quantum BioPharma Ltd. reports reaching the halfway point in patient enrollment for its collaborative PET imaging study with Massachusetts General Hospital in multiple sclerosis. Early imaging data using the [ˆ⁸F]3F4AP tracer show strong signals in acute lesions and potential sensitivity to gray matter lesions.
The imaging approach aims to directly quantify demyelination and myelin repair, which could improve how therapies such as Quantum’s lead candidate Lucid-MS are evaluated. Lucid-MS targets PAD2 to prevent and reverse myelin degradation and has shown a favorable safety profile in prior Phase 1 trials, with an IND for a Phase 2 trial submitted in March 2026.
Quantum also highlights its economic interest in UNBUZZD, retaining 19.84% ownership as of March 31, 2026, plus a 7% royalty on sales until $250 million is paid, after which the royalty rate decreases to 3% in perpetuity.
Quantum BioPharma reported a much stronger liquidity position and key R&D progress for the first quarter of 2026. Combined cash, cash equivalents and digital assets were US$9.8 million as of March 31, 2026, more than double the US$4.1 million at year-end 2025, and management estimates this will fund operations to approximately July 2027.
Cash used in operating activities fell to US$1.66 million, a 60% year-over-year reduction, mainly from lower R&D spending after completing Phase 1 trials. The company filed an IND application with the FDA for its multiple sclerosis candidate Lucid-MS, signed a binding LOI with CRO Allucent for a planned Phase 2 trial, and appointed Dr. Salvatore Napoli as principal investigator. Quantum also highlighted Unbuzzd’s reorganization and new CEO to pursue an IPO, and noted that a U.S. court denied CIBC and RBC’s joint motion to dismiss Quantum’s lawsuit alleging stock market manipulation.